Markets:

Overview

News

Currencies

International

Treasuries

Leap Therapeutics, Inc. - Common Stock (NQ:LPTX)

2.060 UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Leap Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 26, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 14, 2025

Via Benzinga

Leap Therapeutics Slashes R&D Spending ↗

August 14, 2025

Via The Motley Fool

Topics Intellectual Property

Leap Therapeutics: Q4 Earnings Insights ↗

March 18, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 29, 2025

Via Benzinga

These stocks are moving in today's pre-market session ↗

June 23, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

In today's session, these stocks are experiencing unusual volume. ↗

March 27, 2025

Unusual volume stocks are being observed in Thursday's session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 27, 2025

Via Benzinga

Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment

March 26, 2025

Via AB Newswire

Topics Artificial Intelligence

These stocks are the most active in today's session ↗

March 26, 2025

Wednesday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!

Via Chartmill

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer ↗

March 26, 2025

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans.

Via Benzinga

Top movers in Wednesday's pre-market session ↗

March 26, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe ↗

February 12, 2025

Via Stocktwits

The trading volume of these stocks is deviating from the norm in today's session. ↗

January 29, 2025

Which stocks have an unusual volume on Wednesday?

Via Chartmill

This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

January 29, 2025

Via Benzinga

Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session. ↗

January 28, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline ↗

January 28, 2025

While sirexatamab combined with tislelizumab and chemotherapy showed some activity in biomarker-specific populations, the study failed to generate a clear positive signal on progression-free survival...

Via Stocktwits

Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes ↗

January 28, 2025

Leap Therapeutics' Phase 2 data shows sirexatamab improves ORR in colorectal cancer. Gastric cancer studies end due to lack of PFS benefit.

Via Benzinga

Gold Gains 1%; Boeing Shares Rise Following Q4 Results ↗

January 28, 2025

Via Benzinga

These stocks are moving in today's session ↗

January 28, 2025

Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results ↗

January 28, 2025

Via Benzinga

The market is filled with gapping stocks in Tuesday's session. ↗

January 28, 2025

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings ↗

January 28, 2025

Via Benzinga

Topics Stocks

LPTX Stock Earnings: Leap Therapeutics Misses EPS for Q2 2024 ↗

August 12, 2024

LPTX stock results show that Leap Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024 ↗

May 13, 2024

LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 20, 2024

Via Benzinga

LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023 ↗

March 18, 2024

LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 27, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Leap Therapeutics, Inc. - Common Stock (NQ:LPTX)

All News about Leap Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today